Drug Trial Radar · NCT01352221
Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Crohn's Disease (AEGIS-2)
Last checked: Nov 20, 2026Latest source record: Oct 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
128
Actual
Start
Aug 2011
Primary completion
Oct 2013
Study completion Oct 2014
Sponsor
- Lead sponsor
- Shield TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- May 11, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether ST10-021, an oral ferric iron preparation, is safe and effective in the treatment of iron deficiency anaemia (IDA) in subjects with non-active Crohn's Disease (CD).
Conditions
- Iron Deficiency Anaemia
- Inflammatory Bowel Disease
- Crohn's Disease
Interventions
ST10Drug
30 mg capsules to be taken orally twice a day for 12 weeks in double-blind phase
Placebo oral capsuleDrug
Matching placebo capsules for ST10 to be taken orally twice a day for 12 weeks in double-blind phase
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Haemoglobin (Hb) Concentration From Baseline to Week 12 (Full Analysis Set, FAS)Time frame: Baseline to Week 12 - double-blind phase
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.